Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Shenyang Hongqi Pharmaceutical was awarded the “2023 China Chain Pharmacy’s Most Valuable Product for Collaboration” prize.
Category:
Company News
Author:
Source:
Add time:2024-05-30 21:04
From June 27 to 30, the 2023 Misi Conference—China’s Pharmaceutical and Health Industry Symbiosis Summit—was grandly held in Huzhou, Zhejiang, under the theme “Quality Wins: A New Cycle.” As an annual flagship event for the health industry, this year once again brought together leading figures from across the sector.
At the conference, following multiple rounds of voting, Hongqi Pharmaceutical was honored with the title of “2023 China’s Most Valuable Collaborative Product for Chain Pharmacies” (Bango® Dapoxetine Hydrochloride Tablets).
As the only chemically synthesized drug currently approved for the treatment of premature ejaculation (PE), dapoxetine hydrochloride is recommended as a first-line therapy in both domestic and international guidelines for the diagnosis and management of PE. It is estimated that China’s market for PE‑treating medications could reach RMB 1.675 billion in 2023, reflecting a clear upward trend and substantial growth potential.
Hongqi Pharmaceutical listed dapoxetine hydrochloride tablets in September 2021, comprehensively expanded its urology product portfolio, launched its “Happy Life” business line, and implemented a specialized brand‑management strategy for the “Happy Life” segment. Through strategic partnerships, agency‑based co‑promotion, direct supply to pharmacy chains, e‑commerce channels (B2C and O2O), OEM arrangements, and innovative initiatives such as professional retail promotion and services, brand introduction and licensing, and internet‑based medical consultations, the company is actively cultivating the men’s health market.
China’s pharmaceutical retail market is currently undergoing an unprecedented transformation, with chain pharmacies at a critical juncture of upgrading and reinvention. Under the influence of new policies—such as centralized drug procurement and the outflow of prescription drugs—the industry is steadily moving toward greater scale, stronger branding, and increased specialization. Meanwhile, the ongoing deepening of healthcare reform brings both fresh momentum and significant challenges. Against this backdrop, this conference has brought together the industry’s collective strength and expertise, convening leading academics, major pharmaceutical manufacturers, and top-tier executives from the nation’s top 100 pharmacy chains to spark a robust exchange of ideas, rally shared determination, and pursue innovation and progress amid change—ultimately igniting a blaze of insightful collaboration.
Fosun Pharma’s subsidiary, Hongqi Pharmaceutical, was invited to participate in this prestigious event, showcasing its “Happy Life” product line—including dapoxetine hydrochloride tablets and tadalafil tablets—and conducting brand presentations. The company garnered significant attention from attending chain‑store clients, who gathered at its booth for related discussions and exchanges.
Looking ahead, Shenyang Hongqi will continue to maintain its leading position in brand and marketing within the men’s health category, firmly establishing itself in China’s pharmaceutical retail market. It will provide multi‑tiered, diverse, and customizable men’s health products to Chinese pharmacy‑chain customers, striving to become an integral part of Fosun’s “Health · Happiness · Prosperity” well‑being ecosystem and a premier provider of high‑quality products, brands, and services in the domestic happiness‑focused lifestyle sector, thereby contributing to the well‑being of Chinese families.
